Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052480 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT01052480 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 98 participants.
The verdict
NCT01052480, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B. Hospitalized subjects with influenza A or B that have either a low oxygen level or a high respiratory rate will be eligible for study participation. This study will enroll adults, children and pregnant women.
Interventions
- BIOLOGICAL Anti-Influenza Immune Plasma
- DRUG Standard Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01052480
The ClinicalTrials.gov registry entry for NCT01052480 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anti-Influenza Immune Plasma is the first listed.
NCT01052480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01052480 about?
NCT01052480 is a clinical study titled "Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza". This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B. Hospitalized subjects with influenza A or B that have either a low oxygen level or a high respiratory rate will be eligible f...
What is the current status of trial NCT01052480?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2010-12. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01052480?
The interventions under investigation include: Anti-Influenza Immune Plasma (BIOLOGICAL), Standard Care (DRUG).
Who is sponsoring clinical trial NCT01052480?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.